JAVIER
CAMBRONERO SANTOS
Profesor asociado de Ciencias de la Salud
University of Toronto
Toronto, CanadáPublicaciones en colaboración con investigadores/as de University of Toronto (7)
2021
2020
-
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS)
The Journal of urology, Vol. 203, Núm. 6, pp. 1163-1171
-
Reply by Authors
The Journal of urology
2017
-
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)
International Journal of Clinical Practice, Vol. 71, Núm. 5
2016
2015
-
The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: Results of a noninferiority, randomized, phase IIIb trial
Therapeutic Advances in Urology, Vol. 7, Núm. 4, pp. 167-179
2013
-
Mirabegron for the treatment of overactive bladder: A prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
International Journal of Clinical Practice, Vol. 67, Núm. 7, pp. 619-632